The European Commission

R&D

We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United States.

News

Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.